TransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Analysts at Jefferies Financial Group

Key Points

• Jefferies Financial Group has initiated coverage of TransMedics Group (NASDAQ:TMDX) with a "buy" rating and a price target of $145.00, indicating a potential upside of 35.15% from the current stock price.
• The company recently reported quarterly earnings of $0.92 per share, significantly outperforming analysts' expectations and achieving a year-over-year revenue increase of 37.7%.
• Currently, 99.67% of TransMedics Group's stock is owned by institutional investors, reflecting strong interest and confidence in the company's financial performance and future prospects.

Jefferies Financial Group began coverage on shares of TransMedics Group (NASDAQ:TMDX - Get Free Report) in a note issued to investors on Monday,Benzinga reports. The firm set a "buy" rating and a $145.00 price target on the stock. Jefferies Financial Group's price objective points to a potential upside of 35.15% from the stock's current price.

Several other research firms have also commented on TMDX. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target for the company. Oppenheimer boosted their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Evercore ISI initiated coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an "outperform" rating and a $155.00 price objective for the company. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Finally, Zacks Research lowered shares of TransMedics Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $127.18.

TransMedics Group Price Performance

TMDX stock opened at $107.29 on Monday. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a 50-day moving average price of $117.21 and a 200 day moving average price of $112.40. The stock has a market cap of $3.66 billion, a PE ratio of 55.59 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter last year, the business posted $0.35 EPS. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of TransMedics Group by 1.4% in the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company's stock valued at $107,845,000 after purchasing an additional 11,241 shares during the period. Driehaus Capital Management LLC lifted its stake in TransMedics Group by 2.4% in the first quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock worth $52,395,000 after acquiring an additional 17,913 shares during the last quarter. Marshall Wace LLP lifted its stake in TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock worth $73,275,000 after acquiring an additional 394,340 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after acquiring an additional 86,721 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.